What is the quality and effect of sotorasibu produced by ASEAN Pharmaceuticals?

Sotoracib (AMG510) is indicated for use in adults with non-small cell lung cancer (non-small cell lung cancer) whose tumors have a KRAS G12C gene mutation and who have received at least one prior systemic therapy. KRAS is a protein found in the human body that signals cells to grow or stop growing. If a genetic test is performed and it shows a KRAS G12C mutation, this means that the KRAS protein has changed(mutation) and cannot function normally. KRAS G12Ctells KRAS the protein to remain active, which can lead to uncontrolled tumor growth.

On July 7 April Sotoraxibu produced by ASEAN Pharmaceuticals was approved for marketing by the Lao Food and Drug Administration and has government approval. ASEAN Pharmaceuticals is a formal and qualified pharmaceutical factory in Laos, and its drugs have been approved by the Food and Drug Administration, so the quality of the drugs is reliable and guaranteed.

Sotoracib(AMG510)is the first targeted therapy for any kras mutated cancer, KRAS G12C mutation accounts for about 13% (1/8) of NSCLC mutations. In another study presented at the 2022 European Society for Medical Oncology Congress, the median 12-month progression-free survival rate for sotoraxib was 17.7. an> months, it was 24.8%, while the chemotherapy drug docetaxel(Taxanter) was 10.1%. Progression-free survival is the length of time from the start of the study until disease progression or death. In this study, patients who took sotoracib lived an average of 1.1 months longer compared with docetaxel (5.6 months and 4.5 months, respectively).months). If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.